Aktuellt
SENASTE
Idogen continues on a steady path towards clinical trials, which it expects to commence in H1 2021. The pandemic has, however, caused its collaboration partner Radboud to reduce its production capacity, which could imply delays to Idogen's timeline. Cost control remained good in the second quarter and the company assesses that its operations are financed until Q3 2021. We update our fair value to SEK 7-24 per share (SEK 0.8-3.0) following the report, largely reflecting the recent reverse share split.
LÄS MER
